ArticleIndian dermatology online journal2026
Comparative Efficacy of Terbinafine, Itraconazole, and Griseofulvin in Treatment of Steroid-Modified Tinea.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroid-modified tinea or tinea incognito has emerged as a significant challenge in India due to the widespread misuse of topical corticosteroids, leading to chronic, treatment-resistant dermatophytosis. AIM AND
objectivesThis study was performed to compare the efficacy and safety of antifungal drugs: oral terbinafine, itraconazole, and griseofulvin in the treatment of steroid-modified tinea. In addition, patient awareness about steroid misuse and consequent impact on quality of life were also assessed. PATIENTS AND
methodsA total of 90 potassium hydroxide (KOH)-positive patients ( ≥18 years) with tinea corporis, cruris, or faciei, having a history of prior topical steroid use, were randomly assigned to receive terbinafine (250 mg twice a day), itraconazole (100 mg twice a day), or griseofulvin (500 mg twice a day) for eight weeks ( n = 30 each). Clinical severity scores, cure rates, dermatology life quality index (DLQI) scores, steroid misuse patterns, and any adverse drug reactions reported were recorded for each patient.
resultsThe group treated with itraconazole showed highest cure rate (70%) at eight weeks, followed by terbinafine (36.7%) and griseofulvin (26.7%) ( P = 0.529). Clinical severity scores reduced significantly in all three groups by the end of eight weeks (within-group comparison P = 0.001). DLQI scores improved most with itraconazole ( P = 0.003). Regarding a prior history of steroid use in the study population, the misuse of clobetasol propionate was seen in 46.7-76.7%, with 90-100% of patients being unaware of steroid content or its side effects. LIMITATIONS: Limited sample size may have limited statistical ability to detect significant cure rates. Despite intention-to-treat analysis, loss of follow-up may introduce bias. Baseline differences in gender and comorbidities among the study groups may have confounded the observed outcomes. Additionally, the lack of blinding may have influenced outcome assessment.
conclusionItraconazole appears to be the most effective for steroid-modified tinea, with superior clinical and quality-of-life outcomes. Steroid misuse, driven by pharmacist recommendations, underscores the need for public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.